NCT06523777 PRISM: Patient Experiences With PET Imaging in Prostate Cancer
| NCT ID | NCT06523777 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 350 participants |
| Start Date | 2024-07-25 |
| Primary Completion | 2028-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 350 participants in total. It began in 2024-07-25 with a primary completion date of 2028-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this study is to examine patient experiences, health-related quality of life, and decision-making associated with PET imaging for prostate cancer. In particular, Prostate Specific Membrane Antigen (PSMA) PET, a new and more sensitive form of imaging that can help identify metastatic cancer earlier and more reliably.
Eligibility Criteria
Inclusion Criteria: * Documented diagnosis of prostate cancer * Scheduled for their FIRST PSMA PET scan for prostate cancer * English-speaking * Willing and able to complete 4 surveys electronically or on paper at 3 timepoints (within 1 month after PET scan, 3-6 months, 12 months) * Able to use mobile device (smartphone or tablet) or computer with web access to complete study surveys or able to complete paper surveys Exclusion Criteria: * Lack of access to a mobile device (smartphone or tablet) or computer with web access or unable to receive surveys by mail. * Unable to give consent and be enrolled * PET scan is being conducted within a clinical trial
Contact & Investigator
Michael Leapman, MD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT06523777 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06523777 currently recruiting?
Yes, NCT06523777 is actively recruiting participants. Contact the research team at michael.leapman@yale.edu for enrollment information.
Where is the NCT06523777 trial being conducted?
This trial is being conducted at Bridgeport, United States, Derby, United States, Greenwich, United States, New Haven, United States and 3 additional locations.
Who is sponsoring the NCT06523777 clinical trial?
NCT06523777 is sponsored by Yale University. The principal investigator is Michael Leapman, MD at Yale University. The trial plans to enroll 350 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.